CXCR3 and neoplasm: Since we showed that combining CD3 bsAb with vaccination helped recruit fresh peripheral T cells to the tumor via the CXCR3 axis in mouse models, clinical studies are warranted to evaluate if influx of peripheral cells into the tumor also occurs in humans and how priming may impact T-cell fitness pre- and post-CD3 bsAb administration.